Vivos Inc. (OTCQB: RDGL) today announced enhanced cooperation with Exubrion Therapeutics to advance the use of targeted radioactive isotope technology for multiple indications in companion animals.
The two companies have agreed to broaden their joint efforts in several key areas — including shared clinic relationships, licensing coordination, and manufacturing optimization. These initiatives build upon prior collaborations involving device classification, development of clinician training modules, and educational seminars.
About Exubrion Therapeutics
Exubrion Therapeutics is a veterinary radiotherapeutics company dedicated to improving the lives of companion animals through advanced radioisotope technology. The company’s lead product, Synovetin OA®, is an innovative, minimally invasive treatment for osteoarthritis that targets the source of the disease and provides long-lasting joint pain relief. Learn more at www.Exubrion.com.
Read the full press release here.
